Loading stock data…
$9.27-0.14 (-1.54%)
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
Corvus Pharmaceuticals, Inc. in the Healthcare sector is trading at $9.27 with a market capitalization of $1.3B. Wall Street consensus targets $33.14 (7 analysts), implying a +257.7% move over the next 12 months. The stock is currently near its 52-week low of $6.39, remaining 35.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 15 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$19.30M↓ | -$14.88M↓ | -$12.22M↓ | -$10.57M↓ | -$10.26M |
| Net Income | -$17.96M↓ | -$13.69M↓ | -$12.32M↓ | -$10.16M↓ | -$8.00M |
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lea...